Apotex biosimilar of Amgen's Neulasta under FDA review

The FDA has accepted another biosimilar application, this time Apotex's version of pegfilgrastim, which is referenced from Amgen's innovative drug Neulasta, which raked in about $3.6bn in sales in 2013.